News

What’s happening in NF1 research today

NTAP and CTF supported early-phase trial demonstrates shrinkage in pediatric neural tumors

February 6, 2017

Bethesda, MD (December 28, 2016) NCI Press Release: In an early-phase clinical trial of a new oral drug, selumetinib, children with the common genetic disorder neurofibromatosis type 1 (NF1) and plexiform neurofibromas, tumors of the […]

Read More

NTAP Announces latest Francis S. Collins Scholar, Dr. Ashley Cannon

January 18, 2017

Baltimore, MD (January 3, 2017)  Ashley Cannon, Ph.D., M.S., has been named the 2016 winner of the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research, sponsored by the Neurofibromatosis Therapeutic Acceleration Program […]

Read More

NTAP 2016 Cutaneous Neurofibroma Symposium

January 5, 2017

Establishing priorities and advancing the field of NF1 research Introduction to NTAP symposiaNTAP convenes leading researchers and innovators from across multiple fields and scientific backgrounds in regular symposia to establish priorities for the future NF1-related […]

Read More

NTAP Selected as Innovator Presenter for Partnering for Cures Meeting

November 7, 2014

Baltimore, MD (October 1, 2014)  Neurofibromatosis Therapeutic Acceleration Program (NTAP) today announced that they have been selected as an Innovator Presenter at the 6th Annual Partnering for Cures meeting to be held in New York, […]

Read More

Johns Hopkins Announces Winners of Francis S. Collins Scholar Award

November 7, 2014

Baltimore, MD (June 9, 2014)  Two early career physician-scientists, Peter de Blank and Matthew R. Steensma, have been named inaugural winners of the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research, sponsored […]

Read More

NTAP Announces Request for Proposals to Develop Patient Reported Outcome Measures

March 15, 2013

Baltimore, MD (March 15, 2013) Neurofibromatosis Therapeutic Acceleration Program (NTAP) today announced a request for proposals (RFP) for the development of Patient Reported Outcome (PRO) measures that can be used to support clinical development of […]

Read More

NTAP Announces Biomarker Development Idea Challenge

January 15, 2013

Baltimore, MD (January 15, 2013) Neurofibromatosis Therapeutic Acceleration Program (NTAP) today announced the launch of an idea challenge for the development of biomarkers for neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (pNF). Individuals with pNF can […]

Read More

NTAP Announces Request for Proposals to Develop Cell Culture Models of Plexiform Neurofibromas

October 1, 2012

[vc_row][vc_column][vc_column_text margin_bottom=”10″]Baltimore, MD (October 1, 2012) Neurofibromatosis Therapeutic Acceleration Program (NTAP) today announced a request for proposals (RFP) for the development of novel cell culture models for neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (pNF). Cell […]

Read More

NTAP hosts 2012 Plexiform Neurofibroma Research Summit

September 12, 2012

[vc_row][vc_column][vc_column_text margin_bottom=”10″]Baltimore, MD (September 22, 2012) Neurofibromatosis Therapeutic Acceleration Program (NTAP) held its inaugural Plexiform Neurofibroma Scientific Summit on September 20-22, 2012. Held at Nemacolin Woodlands Resort, the summit focused on defining existing resources and […]

Read More

NTAP announces launch of operations

June 8, 2012

[vc_row][vc_column][vc_column_text margin_bottom=”10″]Baltimore, MD (June 8, 2012) Today, the Neurofibromatosis Therapeutic Acceleration Program (NTAP) announced the launch of its operations, dedicated to improving treatment options for individuals with plexiform neurofibromas (pNFs). NTAP is a non-profit organization […]

Read More